Citius Oncology, Inc. (CTOR) Stock Forecast
CTOR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +420.8% from the latest close
- Next earnings
- —
- 52-week range
- $0.49 – $1.79
CTOR analyst ratings
1 analystsNumber of analysts at each rating.
CTOR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CTOR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | $0.00 | $0.00 | $0.00 | −$0.06 | +100.0% | 1 |
| Current fiscal year (FY2026) | −$0.56 | −$0.56 | −$0.56 | −$0.34 | −64.7% | 1 |
| Next fiscal year (FY2027) | $0.10 | $0.10 | $0.10 | −$0.56 | +117.9% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CTOR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $14.3M | $14.3M | $14.3M | +261.9% | 1 |
| Current fiscal year (FY2026) | $13.9M | $13.9M | $13.9M | 0.0% | 1 |
| Next fiscal year (FY2027) | $95.2M | $95.2M | $95.2M | +585.4% | 1 |
CTOR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CTOR revenue: reported and forecast
CTOR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | $0.10 | $0.00 | $0.00 | $0.00 | $0.00 | −100.0% | 0 up · 1 down |
| Current fiscal year (FY2026) | −$0.19 | −$0.60 | −$0.60 | −$0.60 | −$0.56 | +194.7% | 0 up · 1 down |
| Next fiscal year (FY2027) | $0.39 | $0.10 | $0.10 | $0.10 | $0.10 | −74.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CTOR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CTOR beat in 2 of 8.
What analysts expect from CTOR
1 analysts cover Citius Oncology; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 420.8% above the latest close of $0.77. Analysts expect earnings of −$0.56 per share for FY2026, −64.7% from a year earlier. For FY2027 the average estimate is $0.10 per share on revenue of $95.2 million. Citius Oncology beat the EPS estimate in 2 of the last 8 quarters.
Related: CTOR income statement, CTOR key metrics, CTOR chart. See the CTOR stock overview for the latest quote and news.
CTOR forecast FAQ
What is Citius Oncology's price target?
The average analyst price target for Citius Oncology is $4.00, 420.8% above the latest close of $0.77.
Is Citius Oncology a buy, hold or sell?
Of 1 analysts covering Citius Oncology, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Citius Oncology's EPS forecast?
Analysts forecast −$0.56 per share for FY2026 (range −$0.56 to −$0.56); for FY2027 the estimate is $0.10.
What is Citius Oncology's revenue forecast?
The average revenue estimate for FY2026 is $13.9 million, growth of 0.0%; for FY2027 it is $95.2 million.
Does Citius Oncology usually beat earnings estimates?
Citius Oncology reported EPS at or above the analyst estimate in 2 of the last 8 quarters.